Trastuzumab
Brand Names: Ogivri, Herzuma, Herceptin, Ontruzant
Methodology & AI Transparency ⓘ
Trastuzumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in Kit and 150 mg/7.4mL Injection, Powder, Lyophilized, for Solution and manufactured/labeled by Mylan Institutional LLC (NDC 67457-847, 67457-991), Trastuzumab operates within systemic her2/neu receptor antagonist treatment algorithms requiring prescription authorization.
- 2 Real-world patient consensus: Zero-PHI community consensus: 91% favorable across 14 logged regimens (Ogivri, Herzuma).
- 3 Typical cash cost range: Dispensing cost comparison spans $105.30 mail/discount cash up to $257.99 uninsured retail (federal NADAC $2.3900).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Trastuzumab: nausea (8.7%), headache (8.3%), dizziness (6.8%).
Ask our AI Specialists anything about Trastuzumab
Trastuzumab Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in Kit and 150 mg/7.4mL Injection, Powder, Lyophilized, for Solution and manufactured/labeled by Mylan Institutional LLC (NDC 67457-847, 67457-991), Trastuzumab operates within systemic her2/neu receptor antagonist treatment algorithms requiring prescription authorization.
Delivered via Kit and 150 mg/7.4mL Injection, Powder, Lyophilized, for Solution (systemic; NDC 67457-847, 67457-991), Trastuzumab mediates her2/neu receptor antagonist physiological effects manufactured/labeled by Mylan Institutional LLC with dose-dependent receptor occupancy and systemic clearance.
Clinical clearance of Trastuzumab (HER2/neu Receptor Antagonist) relies on systemic clearance of trastuzumab integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 5 to 14 hours per Trastuzumab clinical pharmacology half-life; patients absorbing at Consistent 76%–88% gastrointestinal absorption profile for Trastuzumab bioavailability typically observe target onset around cmax attained 2–3 hours post-administration of trastuzumab.
FDA clinical labeling for Trastuzumab restricts administration in confirmed ige-mediated allergy or cutaneous reaction to trastuzumab (trastuzumab) components; uncompensated hepatic or renal insufficiency incompatible with trastuzumab (kit) clearance across Kit, 150 mg/7.4mL Injection, Powder, Lyophilized, for Solution, 150 mg/7.15mL Injection, Powder, Lyophilized, for Solution, 150 mg/1 Injection, Powder, Lyophilized, for Solution, with self-reported patient tracking dominated by nausea (8.7% of reports), headache (8.3% of reports), dizziness (6.8% of reports).
Reconcile eGFR-adjusted medications before escalating Trastuzumab in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Trastuzumab dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Trastuzumab (Trastuzumab) components
- Uncompensated hepatic or renal insufficiency incompatible with Trastuzumab (Kit) clearance
Logged Side-Effect Incidence (14 Reports)
Trastuzumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Trastuzumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and: What a 4,804-Participant Study Found Pertuzumab improved IDFS in all subgroups, with the greatest improvement in HER2 FISH-low/estrogen receptor-positive tumors. Journal of the National Cancer Institute • 2026-08-01 • Phase III Randomized Trial | N = 4,804 | 96/100 | PMID 41934626 ↗ |
| New Insights on STAT3 activation in HER2-positive breast cancers: Analysis of data from a large: What a 5,694-Participant Study Found This effect was limited to ER-positive tumors. International journal of cancer • 2021-03-15 • Phase III Randomized Trial | N = 5,694 | 90/100 | PMID 33152119 ↗ |
| Can This Approach Help? Inside the Latest Research on Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are The analysis was performed on 174 women (median age, 48 years; range, 24-75 years) who had completed a cardiological assessment at 12 months and reached the end of treatment. JAMA oncology • 2021-10-01 • Phase III Randomized Trial | N = 174 | 88/100 | PMID 34436523 ↗ |
| New Insights on Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously: What a 243-Participant Study Found The PUFFIN final analysis showed, per the primary analysis, that overall efficacy of pertuzumab plus trastuzumab and docetaxel was consistent with CLEOPATRA. Breast cancer research and treatment • 2023-02-15 • Phase III Randomized Trial | N = 243 | 88/100 | PMID 36463547 ↗ |
| Can This Approach Help? Inside the Latest Research on Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted In patients with HER2-positive early BC treated with modern anticancer therapies, young age did not demonstrate either prognostic or predictive value, irrespective of hormone receptor status. Journal of the National Cancer Institute • 2022-08-08 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35512402 ↗ |
Trastuzumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.3900/unit (~$71.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $257.99 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $105.30 / mo | View logs ↓ |
Trastuzumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Trastuzumab RxNorm Concept ID | RXN-67457847-2419 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.3900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $257.99 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $105.30 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Trastuzumab Patient Community, Cohort Filters & Dosage Logs
Cross-verified Trastuzumab (her2/neu receptor antagonist) monograph synthesizing RxNorm RXN-67457847-2419, openFDA FAERS signals, and $105.30–$257.99 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Trastuzumab community threads and patient logs by age, biological sex, dosage, and treatment duration.